Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Kathleen Colson"'
Autor:
Kenneth C. Anderson, Clifton C. Mo, Omar Nadeem, Kelly Masone, Ella L Millard, Irene M. Ghobrial, Giada Bianchi, Mary McKenney, Isabella Hou, Peter Barth, Kathleen Colson, Jacob P. Laubach, Leyla Shune, Virginia Dalton, Paul G. Richardson, Adam S. Sperling, Robert A. Redd, Alexandra Savell, Vaishali Sanchorawala, Nikhil C. Munshi, Laura N. Amweg, Trevor J. Bayliss, Alexandra Distaso
Publikováno v:
Blood
Introduction: Treatment of relapsed and refractory multiple myeloma (RRMM) continues to evolve as most patients are lenalidomide (LEN) refractory at the time of first relapse with its widespread use in both induction and maintenance therapy. Pomalido
Autor:
Dixil Francis, Amitabha Mazumder, Teru Hideshima, Irene M. Ghobrial, Nikhil C. Munshi, John Feather, Constantine S. Mitsiades, Dixie-Lee Esseltine, Laura E. Lunde, Wanling Xie, Robert Knight, Paul G. Richardson, Melissa Alsina, Sundar Jagannath, Jonathan L. Kaufman, Robert L. Schlossman, Kathleen Colson, Diane Warren, Andrzej Jakubowiak, Michelle E. Maglio, Kenneth C. Anderson, Edie Weller, Mary McKenney, Sagar Lonial, David H. Vesole, Noopur Raje
Publikováno v:
Blood. 123:1461-1469
In this prospective, multicenter, phase 2 study, 64 patients with relapsed or relapsed and refractory multiple myeloma (MM) received up to 8 21-day cycles of bortezomib 1.0 mg/m(2) (days 1, 4, 8, and 11), lenalidomide 15 mg/day (days 1-14), and dexam
Autor:
Monica Mitchell, Jonathan L. Kaufman, Paul G. Richardson, L. Gardner, Teru Hideshima, Melissa Alsina, Kathleen Colson, Kenneth C. Anderson, Peter Sportelli, Todd M. Zimmerman, Kathy Giusti, Andrzej Jakubowiak, Colleen K. Harvey, Malathi Kandarpa
Publikováno v:
Blood. 116:3064-3064
Abstract 3064 Introduction: Perifosine (Peri) a novel, oral signal transduction modulator with multiple effects including inhibition of Akt and activation of JNK, has demonstrated clinical activity when combined with dexamethasone (Dex) in patients (
Autor:
Anuj Mahindra, Nikhil C. Munshi, Linda Rivera, Ayman Saad, Irene M. Ghobrial, Sarah Kaster, Kenneth C. Anderson, Noopur Raje, Aliyah R. Sohani, Paulette Jacobs, Edie Weller, Paul G. Richardson, Robert L. Schlossman, Jacob P. Laubach, Wendy Makrides, Parameswaran Hari, Jill N. Burke, Jennifer Adams, Kathleen Colson, Christine Connolly
Publikováno v:
Blood. 116:3051-3051
Abstract 3051 Background: Lenalidomide (Revlimid®, Len) plus dexamethasone (Dex) is approved for the treatment of relapsed or refractory multiple myeloma (MM) patients following ≥1 prior therapy. RAD001, an mTOR inhibitor has been studied as a sin
Autor:
Dixie-Lee Esseltine, Melissa Alsina, Irene M. Ghobrial, Kathleen Colson, Paul G. Richardson, John Feather, Nikhil C. Munshi, Laura E. Lunde, Robert L. Schlossman, Sagar Lonial, Kenneth C. Anderson, Robert Knight, Andrzej Jakubowiak, Sundar Jagannath, Teru Hideshima, David H. Vesole, Constantine S. Mitsiades, Mary McKenney, Amitabha Mazumder, Noopur Raje
Publikováno v:
Blood. 116:3049-3049
Abstract 3049 Background: Single-agent bortezomib (btz) and lenalidomide (len)-dexamethasone (dex) are associated with higher rates of response and improved survival vs dex alone in relapsed MM, and both are approved for treatment of MM pts with ≥1
Autor:
Constantine S. Mitsiades, Kenneth C. Anderson, Kara Kosakowski, Sundar Jagannath, Amitabha Mazumder, Melissa Alsina, Sagar Lonial, Laura E. Lunde, Kathleen Colson, Nikhil C. Munshi, Irene M. Ghobrial, Noopur Raje, Sarah Kennedy, Teru Hideshima, Dixie-Lee Esseltine, Andrzej Jakubowiak, Robert Knight, David H. Vesole, Paul G. Richardson, Mary McKenney
Publikováno v:
Blood. 112:1742-1742
Background: Bortezomib (VELCADE®, Bz) is approved for the treatment of multiple myeloma (MM). Lenalidomide (Revlimid®, Len) plus dexamethasone (Dex) is approved for the treatment of relapsed MM pts following ≥ 1 prior therapy. In a phase 1 study,
Autor:
Noopur Raje, Kenneth C. Anderson, Teru Hideshima, Kathleen Colson, Robert L. Schlossman, Amitabha Mazumder, Sarah Kaster, Dixie-Lee Esseltine, Melissa Farrell, Lawrence Giove, Nikhil C. Munshi, Paul G. Richardson, Robert Knight, Laura E. Lunde, Mary McKenney, Irene Ghobrial, Andrzej Jakubowiak, Sagar Lonial, Sundar Jagannath, Constantine S. Mitsiades
Publikováno v:
Blood. 110:2714-2714
Background: Single-agent bortezomib (VELCADE®, Vel) and lenalidomide (Revlimid®, Rev) plus dexamethasone (Dex) are approved for relapsed MM patients (pts) following ≥1 prior therapy. Preclinical studies show Rev sensitizes MM cells to Vel and Dex
Autor:
Ivy Fearen, Kenneth C. Anderson, Paul G. Richardson, David S. Siegel, Syed Rizvi, L. Sun, Barbara Atkins, Laura McBride, Carol Oerth, Eileen Reilly, Constantine S. Mitsiades, Judy Chiao, Kathleen Colson, Justin L. Ricker
Publikováno v:
Blood. 110:1179-1179
Background: The histone deacetylase inhibitor vorinostat was approved by the United States FDA in October 2006 for the treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma who have progressive, persistent or recurrent dise
Autor:
John J. Densmore, Paul G. Richardson, KC Anderson, L. Gardner, Tara Kendall, Jeffrey P. Allerton, Irene M. Ghobrial, Kathleen Colson, Teru Hideshima, Jeffrey A. Zonder, Aparna Krishnan, Robert Birch, Andrzej Jakubowiak, Thierry Facon, Peter Sportelli, B. Martineau, C. Leister, Jeffrey L. Wolf, Sagar Lonial, I. C. Henderson
Publikováno v:
Blood. 110:1170-1170
INTRODUCTION: Perifosine (peri) is an oral, signal transduction modulator with multiple pathway effects including inhibition of Akt and activation of JNK. In vitro, peri + bortezomib (Velcade®, Vel) shows additive cytotoxicity against MM cells with
Autor:
John J. Densmore, Andrzej Jakubowiak, Robert Birch, Aparna Krishnan, Peter Sportelli, I. C. Henderson, Irene M. Ghobrial, Tara Kendall, L. Gardner, Jeffrey L. Wolf, Kathleen Colson, Seema Singhal, J. Stephenson, J. F. Martin, Dixil Francis, L. Lai, Teru Hideshima, N. Obadike, KC Anderson, Paul G. Richardson, Jayesh Mehta, Kevin Sullivan, Sagar Lonial
Publikováno v:
Blood. 110:1164-1164
INTRODUCTION: Perifosine (peri) is an oral, novel synthetic alkylphospholipid, with multiple effects on signal transduction pathways, including inhibition of Akt and activation of JNK. In vitro studies showed that peri induces cytotoxicity in both MM